Lavie Bio Announces Commercial Expansion of Yalos as Seed-Treatment for Soybean, Following Successful Field Trials

PR Newswire · Nov 12, 2024 20:00

Lavie Bio intends to commence Yalos sales for soybean in 2025 US spring season

REHOVOT, Israel, Nov. 12, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced the commercial expansion of Yalos seed-treatment to soybean, following successful field trials performed in 2024 in the US. Yalos, Lavie Bio's first commercial bio-inoculant product available in the US and Canada, demonstrated yield increase by more than 5% on average, in soybean.

Lavie Bio

US field trials: Soybean treated with Yalos on the left shows increased plant vigor, leading to better plant health and increased yield, in comparison to untreated plants on the right.

Evogene

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Lavie Bio Announces Commercial Expansion of Yalos as Seed-Treatment for Soybean, Following Successful Field Trials

Risk Disclaimer